Cite
HARVARD Citation
Kito, Y. et al. (n.d.). 606TiPRandomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G. Annals of oncology. p. . [Online].